Endotoxin-Induced Abortion in Early Pregnant Gilts and Its Prevention By

Total Page:16

File Type:pdf, Size:1020Kb

Endotoxin-Induced Abortion in Early Pregnant Gilts and Its Prevention By Acta vet. scand . 1990,31, 347-358. Endotoxin-induced Abortion inEarlyPregnantGilts andits Prevention by F1unixin Meglumine By Nicholas Cort and Hans Kindahl Department of Obstetrics and Gynaecology, College ofVeterinary Medicine, Swedish University of Agricultural Sciences, Uppsala, Sweden. Cort, N. and H. Kindahl: Endotoxin-induced abortion in early pregnant gills and Its prevention by flunixin megJumine. Acta vet. scand. 1990, 31, 347-358. - The objective ofthe study was to examine the effect ofendotoxin on early pregnancy in gilts and to test the potential of flunixin megJumine (FM), a cyclooxygenase inhi­ bitor, to counteract abortifacient action of the endotoxin. Ten gilts at 30 days ge­ station were used in the experiment. Eight were injected with lipopolysaccharide (LPS) of Salmonella typhimurium, while 2 were treated with 500 I1g c1oprostenol (CP). Six of the LPS-injected gilts were treated with a total of 4 mg/kg body weight FM in 2 different dose regimens. Clinical observations were recorded and plasma levels of 15-keto-l3, i4-dihydro-PGF:za, progesterone and estrone sulfate (ES) were determined with radioimmunoassay. LPS induced typical signs of endotoxemia and a monophasic fever in all LPS­ treated gilts. No antipyretic effect ofFM was observed. The CP-treated gilts abor­ ted within 34 h as did the gilts treated by LPS only . Of the 6 LPS + FM-treated gilts, I aborted within 34 h, while 5 maintained gestation. These were aborted about a week later by CP and the aborted fetuses anatomically examined. Two of the litters were lost (devoured by the dams), 2 showed no signs ofearlier death and I showed extensive fetal death. The PGF2a metabolite concentrations increased at least 10 fold immediately after the LPS injection. Progesterone plasma concentration decreased rapidly. A 5-10 fold increase in the plasma metabolite levels accompanied all abortions. CP cau­ sed no immediate change in the PGF:za metabolite levels, but the abortion-related response was similar to that in LPS-injected gilts. In the FM-treated gilts, the LPS­ induced PGF:za metabolite response was rudimentary and the progesterone decrea­ se temporary in nonaborting gilts. The elevated concentrations of ES decreased within 48 h in gilts aborting at 30 days gestation, while in nonaborting gilts a slow, graduate decrease of ES occurred within 3-5 days of the LPS injection. These re­ sults indicate that FM apparently suppressed LPS-induced prostaglandin synthe­ sis and thus prevented luteolysis and abortion in early pregnant gilts. Introduction (Rieder & Thomas 1960, Dennis 1966, Cul Endotoxins of Gram-negative bacteria ad­ bertson & Osburn 1980) and the endotoxin­ ministered to pregnant animals cause abor­ induced synthesis of endogenous prostag­ tion and fetal death. Two major mechanisms landins (PG), among which PGF2a may cau­ are thought to be responsible for the gesta­ se premature regression ofthe corpus luteum tion failure: Disseminated intravascular coa­ (c.l.) and abortion (Roberts et al. 1975). gulation and endothelial damage causing Abortion induced by endotoxin in 60-80 malfunction of the placenta and fetal death days pregnant sows (Wratha// et al. 1978, Acta vel. sc:and. vol.31 no. 3 • 1990 348 N. Cart & H. Kindahl Cort et al. 1986) showed similar course and being involved in both luteolytic and fetopa­ hormonal pattern as abortion induced by thic effect of endotoxin. PGF 2a or CP (Wrathall et 01. 1978, Cort et Luteolysis and expulsion of fetuses in sows 01. 1986,Podany et 01. 1982). These findings occur within 40 h of endotoxin injection , support the theory that the luteolytic effect which does not allow a possible primary fe­ of endotoxin was the principal abortifacient topathic effect of endotoxin to be distinguis­ factor (Cort et 01. 1986). In contrast, abor­ hed from the secondary fetal damage caused tion was not induced by endotoxins in 80­ by the process of expulsion (Wrathall et 01. 100days pregnant sows, indicating increased 1978, Cort et 01. 1986). Removing of the PG resistance to abortifacient factors in late ge­ involvement in the mechanism of initiation station in the pig (Cort & KindahI1986). of abortion may bring some light upon the Early gestation in the pig, as in other animal actual role of PGs in the pathogenic effect species, is generally more sensitive to dama­ on gestation . ge than mid to late gestation. The embryonic Flunixin meglumine (FM) is a non-steroidal phase is characterized by a dramatic growth antiinflammatory drug, which has been used and development of tissues and organs and for the past 10 years mainly in horses with rapid development of the placenta. Vulnera­ colic of musculoskeletal disorders (Houdes bility to infectious diseases is high, as the hell & Hennessey 1977, Vernimb & Hennes conceptus is not immunologically competent sey 1977). FM was found to effectively coun­ until 60-70 days of prenatal age (Wang et 01. teract experimental endotoxemia in horses 1973, WrathaIl1980). Therefore early gesta­ and dogs (Bottoms et 01. 1981, Turek et 01. tion in the pig would have been expected to 1985, Hardie et 0/1987). The antiinflamma­ be at least as sensitive to endotoxin as mid tory effect is based on potent cyclooxygena­ gestation . However, what the embryonic se inhibition, preventing metabolism of ara­ phase has in common with the period from chidonic acid to vasoactive PGs and throm­ 80 days to term is increased plasma concen­ boxanes (Moore et 01. 1986). trations of estrone sulfate, synthetised by the The aims of the present study were to i) inve­ conceptus (Robertson & King 1974).A num­ stigate the effect of bacterial endotoxin on ber of studies on the early gestation in the pig early pregnancy in gilts by means of clinical indicated that estrogens have an antiluteoly­ observations and analysis of blood progeste­ tic/luteotropic function (Bazer & First rone, estrone sulfate and plasma metabolite 1983). of PGF 2a, 15-keto-13, 14-dihydro-PGF2a, ii) Harper & Skarnes (1972) in studies involved to compare these results to the earlier obtai­ in preventing the abortifacient effect of en­ ned ones in mid/late gestation and iii) to in­ dotoxins found that 1) injection of PGF2a vestigate the effect of FM on the synthesis produced the same extent of abortion or in­ and release of PGF2a and the possibility of trauterine fetal death in mice as endotoxin; preventing endotoxin-induced abortion or 2) progesterone or indomethacin prevented fetal death by treatment with FM. endotoxin-induced abortion, but not fetal death , 3) indomethacin plus cyproheptadine Material and methods (serotonin inhibitor) treatment prevented Ten sexually mature Hampshire x Landrace both abortion and fetal death in endotoxin­ x Yorkshire gilts were purchased from a injected mice. These results implicate PGs commercial herd , housed individually and Acta vel. scand. vol. 31 no. 3 • 1990 Endotoxin-induced abortion in gilts 349 fed a standard ration. After observation of Student's t-test was used for analysis of dif­ at least I normal estrous cycle the gilts were ference between the pairs of mean tempera­ inseminated or mated by a boar. Pregnancy tures of LPS + FM-treated gilts in the pre­ was confirmed by a Doppler instrument sent study and LPS-treated gilts from a re­ (Medata System Ltd., Yapton, England) at cent clinical study, which was performed un­ 25 days after service. Jugular vein catheters der the same conditions (Cort 1986). were inserted surgically under general anes­ thesia, 5-3 days prior to the experiment (Ro Results driguez-Martinez & Kunavongkrit 1983). At The clinical response to LPS injections at 30 30 days of gestation (±2), 2 gilts were injec­ days of gestation were arbitrarily characteri­ ted i.rn. with 500 ug cloprostenol (CP) and 8 zed by a scale from no response (-) to severe gilts were injected i.v. with 2 ug/kg body signs (+ + +) of endotoxemia (Table I). weight (b. w.) lipopolysaccharide (LPS) of These included various degrees of fever, vo­ Salmonella typhimurium SH (4809) (Svens­ miting, circulatory shock, dyspnea, ataxia son & Lindberg 1978, Lindberg et al. 1983). and anorexia. LPS injections were followed Six of the LPS-treated gilts were injected i.v. by a severe clinical syndrome, while no clini­ with 2 mg/kg b.w. flun ixin meglumine (FM) cal response was observed after CP injec­ (Finadyne, Schering Corp., Kenilworth, tions. All the typical signs of the syndrome N.J ., USA), 12 h prior to the LPS inject ion . were present i LPS + FM-treated gilts al­ Further treatment by FM was performed in a though none showed as severe clinical endo­ relat ionsh ip to the LPS injection as follows: toxemia as the LPS-treated ones. The dura­ 2 gilts, 2 mg/kg b.w. at -2 and + 10h, 4 gilts, tion of the clinical signs was between I and 8 I mg/kg b.w, at -2, +2, +6 and + 10 h. h after injection (a.i.), Anorexia usually per­ Clinical observations were made and rectal sisted until next day. Yellow discoloration of temperature periodically taken in all ani­ the plasma was observed between 3 and 12 mals. Blood samples for hormone analysis a.i . in both LPS-treated and LPS + FM-trea­ were collected at intervals varying between I ted animals. and 12 h. The blood was immediately centri­ Rectal temperature remained within physio­ fuged and plasma stored at -20°C. Gilts logical range in CP- injected gilts. The which did not abort due to the LPS injection LPS + FM-treated gilts demonstrated a mo­ were treated within 5 to 8 days with CP, 500 nophasic fever curve beginning with a sharp ug i.m. The aborted fetuses and fetal mem­ rise immediately after the LPS injection and branes were anatomically examined. maintaining above 40°C for 2-5 h a.i.: a gra­ The experimental animals were further ob­ dual decrease occurred towards the end of served through the first estrus post abortum.
Recommended publications
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares
    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0269724 A1 KRANTZ (43) Pub
    US 20110269724A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0269724 A1 KRANTZ (43) Pub. Date: Nov. 3, 2011 (54) COMBINATION THERAPY WITH Publication Classification NON-SELECTIVE COXINHIBITORSTO (51) Int. Cl. PREVENT COX-RELATED GASTRIC A6II 3/44 (2006.01) INURES A6II 3/66 (2006.01) A613/60 (2006.01) (75) Inventor: Alexander KRANTZ, (US) A613/618 (2006.01) A613/603 (2006.01) A6IP 7/06 (2006.01) (73) Assignee: Cortria Corporation, Needham, A6IP II/06 (2006.01) MA (US) A6IP 9/02 (2006.01) A6IP 25/06 (2006.01) (21) Appl. No.: 13/100,204 A6IP 7/06 (2006.01) A6IP 9/10 (2006.01) A6IP 9/08 (2006.01) (22) Filed: May 3, 2011 A6II 3/545 (2006.01) A6IP 29/00 (2006.01) Related U.S. Application Data (52) U.S. Cl. ......... 514/161; 514/356; 514/355; 514/352: 514/226.5 (62) Division of application No. 1 1/715,660, filed on Mar. (57) ABSTRACT 8, 2007. The present invention is directed to nicotinamide, nicotina mide derivatives and prostaglandin mimetics, alone or in (60) Provisional application No. 60/780.264, filed on Mar. combination with an NSAID, and their use in treating pain, 8, 2006. inflammation, and/or gastrointestinal toxicty, US 2011/0269724 A1 Nov. 3, 2011 COMBINATION THERAPY WITH began marketing Arthrotec for the treatment of arthritis in NON-SELECTIVE COXINHIBITORSTO patients at risk for developing GI ulcers. This product con PREVENT COX-RELATED GASTRIC tains misoprostol (a cytoprotective prostaglandin) and the INURES NSAID diclofenac. Although patients administered Arthro tecTM do have a lower risk of developing ulcers, they may RELATED APPLICATION experience a number of other serious side effects such as diarrhea, severe cramping and, in the case of pregnant 0001.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Veterinary Medicines
    VETERINARY MEDICINES A compact collection of information on Veterinary drugs/medicines in practice Prepared By : Dr. ANWAR ALAM KHAN eMail and FaceBook : [email protected] Sep-2013 CHAPTERS 1 Gastrointestinal & Hepatobiliary System 2 Infection and Infestations 3 Cardiovascular System 4 Nervous System 5 Respiratory System 6 Allergic Disorders 7 Urinary System 8 Genital System 9 Eye & Ear 10 Topical Applications 11 Nutrition and Metabolism 12 Exclusive Formulations 13 Surgical 14 Livestock Biologicals 15 Diagnostics 16 Ayurvedics Page 2 1...Gastrointestinal & Hepatobiliary System GASTROINTESTINAL & HEPATOBILIARY SYSTEM Antemetics PROMETHAZINE Phenothiazines. Anti-Histaminic, H1 receptar antagonist Phenergan NPIL Promethazine inj 2ml Dog 1-2ml--IM or Nausea, Vomition Slow-IV syp 60 ml tab 10mg Dog 25mg DOMPERIDONE Dopamine receptar Antagonist Domstal Torrent Domperidone drops 5 ml Dog Puppies, 2--3 Nausea, Vomiting. drops susp 30 ml Dog 5-10 ml orally tab 5,10,20 mg Dog 1-2 tab before meals Vomistop Cipla Domperidone drops 30ml Dog 5-10 ml tab 10mg Dog 1-2 tab METACLOPRAMIDE Perinorm IPCA Metaclopramide inj 2ml, 10ml Dog 0.05~2ml--IV Nausia, Vomition liq 30 ml Dog 5-10 ml tab 5mg, 10mg, Dog 5-10 mg DT-5mg ONDANESTRON Belongs to the class of serotonin (5HT3) antagonists Emeset Cipla Ondanestron inj 2ml, 4ml Dog 2-4 ml Nausea, Vomiting syp 30 ml Dog 5-10 ml orally tab 4mg, 8mg Dog 4mg, 8mg Ondem Alkem Ondanestron inj 2ml, 4ml Dog 1--2 ml, IM Nausea, Vomiting (2mg/ml) susp 30 ml Dog Page 3 1...Gastrointestinal & Hepatobiliary System Antacids,
    [Show full text]
  • Persistent Breeding-Induced Endometritis in Mares—A Multifaceted Challenge: from Clinical Aspects to Immunopathogenesis and Pathobiology
    International Journal of Molecular Sciences Review Persistent Breeding-Induced Endometritis in Mares—A Multifaceted Challenge: From Clinical Aspects to Immunopathogenesis and Pathobiology Igor F. Canisso 1,*, Lorenzo G.T.M. Segabinazzi 1,2 and Carleigh E. Fedorka 3 1 Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Champaign, IL 61802, USA; [email protected] 2 Department of Animal Reproduction and Veterinary Radiology, Faculty of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Botucatu 18618-000, São Paulo, Brazil 3 The Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY 40503, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-2172809040 Received: 20 December 2019; Accepted: 7 February 2020; Published: 20 February 2020 Abstract: Post-breeding endometritis (i.e., inflammation/infection of the endometrium), is a physiological reaction taking place in the endometrium of mares within 48 h post-breeding, aimed to clear seminal plasma, excess sperm, microorganisms, and debris from the uterine lumen in preparation for the arrival of an embryo. Mares are classified as susceptible or resistant to persistent breeding-induced endometritis (PBIE) based on their ability to clear this inflammation/infection by 48 h post-breeding. Mares susceptible to PBIE, or those with difficulty clearing infection/inflammation, have a deficient immune response and compromised physical mechanisms of defense against infection. Molecular pathways of the innate immune response known to be involved in PBIE are discussed herein. The role of the adaptive uterine immune response on PBIE remains to be elucidated in horses. Advances in the pathobiology of microbes involved in PBIE are also revised here.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Legislative Status of Veterinary Medicinal Products in Egypt
    Legislative Status of Veterinary Medicinal Products in Egypt TECHNICAL REPORT Under action A2.1 of the Egyptian Vulture New LIFE project (LIFE16 NAT/BG/000874) Hana Y. ElSafoury Nature Conservation Egypt (NCE) 2020 Recommended citation ElSafoury, H. 2020. Legislative Status of Veterinary Medicinal Products in Egypt. Technical report under action A2 of the Egyptian Vulture New LIFE project. Nature Conservation Egypt, Egypt. 55 p. Subject and purpose of the report This report is written under action A2.1 of the Egyptian Vulture New LIFE Project (LIFE16 NAT/BG/000874; www.LifeNeophron.eu), in regard to desk research of legislation and publicly available information on VMPs and NSAIDs. This project is funded by the European Commission and co-funded by the “A. G. Leventis Foundation.” The implementation of the project is done by global partners of BirdLife International1 as well as APLORI, CMS’ Raptors MoU and Green Balkans. The NCE2 is contributing to this project as part of Birdlife Middle East and Birdlife Africa. The main goal of Action A2 is to identify the scale and significance of negative impacts of the use of antibiotics and other VMPs, and in particular NSAIDs in livestock farming on EV populations and propose alternatives. More specifically, this study aims to: Explore the use of VMPs with a proven negative effect on vultures with emphasis on NSAIDs aceclofenac, ketoprofen, carprofen, flunixin, diclofenac, and nimesulide. In addition, all medications containing “fenac”, as well as metamziole (also known as “analgin”), ibuprofen, mefenamic acid, tolfenamic acid, paracetamol (also known as acetaminophen), phenylbutazone, carprofen and piroxicam would be studied with priority, because their impact on vultures was expected to be also strongly negative.
    [Show full text]
  • Index Vol. 16-23
    233 Index Vol. 16-23 The references of the Subject Index are given in the language of the respective contribution. Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgeftihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. A 17 Abortion, therapeutic 457,460 23 Acetylsalicylic acid (Aspirin®) 114 20 Academic research 169 16 O-Acetylserin-Sulfhydrylase A 390 18 Acanthocheilonema perstans 142 17 Acetylstrophanthidin 35 18 Acanthocheilonema streptocerca 142 22 Achromycin® (tetracycline) 53 22 Acaprin® (quinuronium sulfate) 42 19 Acidosis 529 20 Acebutolol 33, 36, 229 18 Acid phosphotase 66 18 Acedapson (Hansolar®, 4',4"'-sulfonylbis­ 16 Aconitase-Isomerase 436 acetanilide) 108, 156 17 Aconitine 35,46 17 Acedist® (bromfenofos, Ph 1882) 113, 134, 17 Acranil 119, 152 278 17 Acrichine® (quinacrine) 119 18 Aceperone 437 17 Acridine 295 16 Acetacetat-Decarboxylase 414 16 Acriftavin 100 17 2-Acetamido-5-nitrothiazole 261 17 Acrolein 358 17 Acetanilide 23, 497 18 Acronine 440 20 Acetanilide 400 21 Acrosin 366 23 Acetanilide 212 21 Acrylamide 186 20 Acetazolamide (Diamox®) 209,417 17 Actamer® (bithionol) 114,297 21 - 114 22 Actamer® (bithionol) 46 22 Acetohexamide (Dymelor®) 81 16 Actinomycin I 298 17 Acetohydroxamic acid 348 16 Actinomycin IV 298 17 Acetone 13, 17 16 Actinomycin V 298 16 Acetophenone 260 17 Actinomycin C, (actinomycin D) 376 17 2-Acetoxy-4' -chloro-3,5-diiodobenzanilide 16 Actinomycin D (actinomycin C" (clioxanide) 114,135,164,277,281
    [Show full text]
  • Publication of Interim Decisions Amending, Or Not Amending, the Current Poisons Standard, June 2018 7 June 2018
    Publication of interim decisions amending, or not amending, the current Poisons Standard, June 2018 7 June 2018 Proposed amendments to the Poisons Standard referred to expert advisory committee Subdivision 3D.2 of the Therapeutic Goods Regulations 1990 (the Regulations) sets out the procedure to be followed in circumstances including where the Secretary receives an application under section 52EAA of the Therapeutic Goods Act 1989 (the Act) to amend the current Poisons Standard and decides to refer the proposed amendment to an expert advisory committee. Under regulation 42ZCZK, these procedures require (among other things) the Secretary to publish (in a manner the Secretary considers appropriate) a notice specifying the expert advisory committee to which the proposed amendment will be referred, the date of the meeting of the committee and details of the proposed amendment. Pursuant to regulation 42ZCZK, the Secretary must invite public submissions to be made to the expert advisory committee by a date mentioned in the notice as the closing date, allowing at least 20 business days after publication of the notice. Such a notice relating to the interim decisions referred to herein was made available on the TGA website on 21 December 2017 and the opportunity to make submissions closed on 2 February 2018. Public submissions received on or before this closing date were published on the TGA website at Consultation: Proposed Amendments to the Poisons Standard - ACCS, ACMS and Joint ACCS-ACMS meetings, March 2018 in accordance with subregulation 42ZCZL(3). Under regulation 42ZCZN of the Regulations, the Secretary, after considering the advice or recommendation of the expert advisory committee, must (subject to regulation 42ZCZO) make an interim decision in relation to the proposed amendment.
    [Show full text]